Insights & Resources

Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Shale maturation and technological innovation impact IP valuations, influencing long-term asset value and productivity in the oil and gas industry.

Companies looking to transform their operations through AI will need to guard against risk from vendors without a SOC 2 report. Learn more here.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Weaver’s current guidance on navigating the AI landscape includes tips to help avoid deceptive tactics and questions to ask when vetting a vendor.

Dashboards are catalysts for decision-making and operational excellence when businesses incorporate user-centric design and include key insights and alerts.

Leverage digital transformation and IT optimization to drive business success by harnessing contextualized data, streamlining processes and fostering innovation.

Unlock AI's potential with quality data. Learn key steps to build a strong data governance framework, integrate data and foster a data-driven culture for AI success.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.